Tennessee Valley Asset Management Partners Makes New $36,000 Investment in Pfizer Inc. (NYSE:PFE)

Tennessee Valley Asset Management Partners bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,236 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Essex LLC increased its stake in Pfizer by 14.8% in the fourth quarter. Essex LLC now owns 75,763 shares of the biopharmaceutical company’s stock worth $2,181,000 after purchasing an additional 9,749 shares during the period. Braun Bostich & Associates Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at $290,000. Wealth Effects LLC increased its stake in shares of Pfizer by 1.5% during the fourth quarter. Wealth Effects LLC now owns 57,321 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 828 shares during the period. Sutton Place Investors LLC purchased a new position in shares of Pfizer during the fourth quarter valued at $802,000. Finally, Sapient Capital LLC purchased a new position in shares of Pfizer during the fourth quarter valued at $1,544,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2 %

Pfizer stock opened at $26.32 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.23 and a 52 week high of $40.37. The company has a market capitalization of $149.04 billion, a price-to-earnings ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The stock has a 50-day moving average price of $27.07 and a 200 day moving average price of $28.52.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 earnings per share. The company’s revenue was down 41.3% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PFE shares. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.